NEW YORK (GenomeWeb News) – Invitrogen announced yesterday that its board of directors has approved a two-for-one stock split.
 
The Carlsbad, Calif.-based firm said that shareholders of record on May 16 will receive on May 27 one additional share for each share held. The company had approximately 48.9 million shares of common stock outstanding as of the end of the first quarter on March 31.
 
Invitrogen’s shares closed at $93.57 in Wednesday trade on the Nasdaq.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.